• This is the first evidence-based real world data in Chinese hypertensive patients which demonstrates the efficacy and safety of Val/Aml (80/5 mg) single pill combination.

• This study is a prospective, multicenter, open-label, post-marketing observational study including 11,422 Chinese adults (≥18 years) with essential hypertension from 238 sites of 29 provinces.

• The results showed compared with levels in baseline, a significant reduction of 27.1 mm Hg in mean sitting systolic blood pressure and 15.2 mm Hg in mean diastolic blood pressure at week 8.

• The blood pressure-lowering efficacy of valsartan/amlodipine single-pill combination (SPC) was independent of age and comorbidities.

• The outcomes of this SPC were found to be safe and tolerable with low incidences of adverse events.

This summary slide represents the opinions of the authors. Sponsorship for this study and article processing charges was funded by Novartis Pharmaceuticals (China). The authors acknowledge Amit Bhat (PhD) and Salini Vasantha (PhD), Indegene Lifesystems Pvt. Ltd., for providing the necessary writing assistance and editorial support towards the development of the manuscript. This support was funded by Novartis. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).